Investor Alert: Pomerantz Law Firm Investigates Novartis AG for Potential Securities Fraud
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Novartis AG and certain of its officers. The investigation follows a September 8, 2026 press release stating that the Phase III HARBOR study evaluating del-desiran in patients with myotonic dystrophy type 1 did not meet its primary endpoint. On this news, Novartis's American Depositary Shares (ADS) dropped $22.29 per ADS or 13.93%, closing at $137.70 on September 8, 2026. The firm is seeking investors to join a potential class action and has provided contact details for interested parties. Pomerantz LLP, known as one of the leading firms in corporate litigation, continues its tradition of fighting securities fraud cases established by founder Abraham L. Pomerantz.
Tickers: $NVS